Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Activation of the STRIKE trial: pembrolizumab and tivozanib in RCC

Bradley McGregor • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Pembrolizumab Tivozanib
STRIKE

Bradley McGregor, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the STRIKE trial (NCT06661720), which will assess short term intensified adjuvant pembrolizumab and tivozanib for high-risk renal cell carcinoma (RCC). Patients who are eligible for the KEYNOTE-564 trial (NCT03142334) will be recruited to this trial and the trial will ultimately assess the efficacy of combining VEGF inhibitors with immunotherapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bradley McGregor

2025 updates of the DAD-IO trial in treatment-naïve urothelial carcinoma
1:21
2025 updates of the DAD-IO trial in treatment-naïve urothelial carcinoma
Bradley McGregor • 13 Feb 2025
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
2:15
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
Bradley McGregor • 13 Feb 2025
Exposure-response analysis of tivozanib in renal cell cancer treatment
1:28
Exposure-response analysis of tivozanib in renal cell cancer treatment
Bradley McGregor • 13 Feb 2025
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
4:21
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
Bradley McGregor • 22 Oct 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals